Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Avaliação de segurança e eficácia a longo prazo de Lunsekimig (SAR443765) em participantes adultos com asma moderada a grave. (AIRPHRODITE)

18 de setembro de 2026 atualizado por: Sanofi

Um estudo de extensão aberto para avaliar a segurança e eficácia a longo prazo do Lunsekimig subcutâneo em participantes adultos com asma moderada a grave que participaram do estudo DRI16762

This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.

The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.

Visão geral do estudo

Status

Inscrevendo-se por convite

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

900

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Leipzig, Alemanha, 04347
        • Investigational Site Number : 2760001
      • Mainz, Alemanha, 55128
        • Investigational Site Number : 2760005
      • Buenos Aires, Argentina, 1121
        • Investigational Site Number : 0320005
      • Buenos Aires, Argentina, 1414
        • Investigational Site Number : 0320004
      • Buenos Aires, Argentina, 1425
        • Investigational Site Number : 0320001
      • Buenos Aires, Argentina, 1122
        • Investigational Site Number : 0320012
      • Buenos Aires, Argentina, 1425
        • Investigational Site Number : 0320011
      • La Plata, Buenos Aires, Argentina, B1904CUL
        • Investigational Site Number : 0320003
      • Mendoza, Argentina, 5500
        • Investigational Site Number : 0320009
      • Mendoza, Argentina, 5500
        • Investigational Site Number : 0320015
      • Santa Fe, Argentina, 3000
        • Investigational Site Number : 0320010
    • Buenos Aires
      • Berazategui, Buenos Aires, Argentina, 1886
        • Investigational Site Number : 0320007
      • Lobos, Buenos Aires, Argentina, 7240
        • Investigational Site Number : 0320013
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320002
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320006
      • Rosario, Santa Fe Province, Argentina, 2000
        • Investigational Site Number : 0320020
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
        • Investigational Site Number : 0320008
      • Rio de Janeiro, Brasil, 22241-180
        • CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760006
      • São Paulo, Brasil, 05403-000
        • Incor - Instituto do Coracao- Site Number : 0760011
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 40060-330
        • Associacao Proar- Site Number : 0760003
    • Goiás
      • Goiânia, Goiás, Brasil, 74605-020
        • Universidade Federal de Goias- Site Number : 0760007
    • Paraná
      • Curitiba, Paraná, Brasil, 80030-110
        • CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
    • Pernambuco
      • Recife, Pernambuco, Brasil, 50070-550
        • Instituto de Medicina Integral Professor Fernando Figueira- Site Number : 0760009
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90610-000
        • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
    • Santa Catarina
      • Blumenau, Santa Catarina, Brasil, 89030-101
        • Hospital Dia do Pulmão- Site Number : 0760005
    • Ontario
      • Ajax, Ontario, Canadá, L1S 2J5
        • Investigational Site Number : 1240013
      • Hamilton, Ontario, Canadá, L8N 4A6
        • Investigational Site Number : 1240003
    • Quebec
      • Sherbrooke, Quebec, Canadá, J1H 5N4
        • Investigational Site Number : 1240004
      • Trois-Rivières, Quebec, Canadá, G8T 7A1
        • Investigational Site Number : 1240001
    • Biobio
      • Concepción, Biobio, Chile, 4070094
        • Investigational Site Number : 1520013
    • Maule Region
      • Talca, Maule Region, Chile, 3465584
        • Investigational Site Number : 1520001
    • Reg Metropolitana de Santiago
      • Recoleta, Reg Metropolitana de Santiago, Chile, 8420000
        • Investigational Site Number : 1520015
      • Santiago, Reg Metropolitana de Santiago, Chile, 7500587
        • Investigational Site Number : 1520006
      • Santiago, Reg Metropolitana de Santiago, Chile, 7500692
        • Investigational Site Number : 1520005
      • Santiago, Reg Metropolitana de Santiago, Chile, 7500698
        • Investigational Site Number : 1520004
      • Santiago, Reg Metropolitana de Santiago, Chile, 7750495
        • Investigational Site Number : 1520002
    • Valparaiso
      • Quillota, Valparaiso, Chile, 2260877
        • Investigational Site Number : 1520008
      • Viña del Mar, Valparaiso, Chile, 2531172
        • Investigational Site Number : 1520011
      • Viña del Mar, Valparaiso, Chile, 2540364
        • Investigational Site Number : 1520012
      • Beijing, China, 100144
        • Investigational Site Number : 1560011
      • Changchun, China, 130021
        • Investigational Site Number : 1560010
      • Changsha, China, 410015
        • Investigational Site Number : 1560017
      • Chengde, China, 067020
        • Investigational Site Number : 1560021
      • Guangzhou, China, 510150
        • Investigational Site Number : 1560009
      • Guangzhou, China, 510000
        • Investigational Site Number : 1560053
      • Guangzhou, China, 510163
        • Investigational Site Number : 1560001
      • Guiyang, China, 550002
        • Investigational Site Number : 1560037
      • Hefei, China, 230032
        • Investigational Site Number : 1560006
      • Hohhot, China, 010050
        • Investigational Site Number : 1560014
      • Lanzhou, China, 730000
        • Investigational Site Number : 1560030
      • Nanchang, China, 330006
        • Investigational Site Number : 1560007
      • Pingxiang, China, 337055
        • Investigational Site Number : 1560002
      • Shanghai, China, 200433
        • Investigational Site Number : 1560013
      • Shenyang, China, 110004
        • Investigational Site Number : 1560015
      • Taiyuan, China, 030001
        • Investigational Site Number : 1560057
      • Tianjin, China, 300211
        • Investigational Site Number : 1560055
      • Wenzhou, China, 325027
        • Investigational Site Number : 1560005
      • Wuhan, China, 430030
        • Investigational Site Number : 1560003
      • Wuhan, China, 430030
        • Investigational Site Number : 1560022
      • Xuzhou, China, 221006
        • Investigational Site Number : 1560004
      • Yangzhou, China, 225000
        • Investigational Site Number : 1560016
      • Zhanjiang, China, 524004
        • Investigational Site Number : 1560012
    • Seoul-teukbyeolsi
      • Seoul, Seoul-teukbyeolsi, Coréia do Sul, 03722
        • Investigational Site Number : 4100001
      • Seoul, Seoul-teukbyeolsi, Coréia do Sul, 03080
        • Investigational Site Number : 4100002
      • Seoul, Seoul-teukbyeolsi, Coréia do Sul, 05030
        • Investigational Site Number : 4100004
      • Seoul, Seoul-teukbyeolsi, Coréia do Sul, 05505
        • Investigational Site Number : 4100006
      • Seoul, Seoul-teukbyeolsi, Coréia do Sul, 06351
        • Investigational Site Number : 4100005
      • Madrid, Espanha, 28007
        • Investigational Site Number : 7240008
      • Madrid, Espanha, 28010
        • Investigational Site Number : 7240011
    • Catalunya [Cataluña]
      • Barcelona, Catalunya [Cataluña], Espanha, 08017
        • Investigational Site Number : 7240009
    • Arizona
      • Chandler, Arizona, Estados Unidos, 85224
        • Chandler Clinical Research Trials- Site Number : 8400075
      • Tucson, Arizona, Estados Unidos, 85712
        • Tucson Clinical Research Institute- Site Number : 8400085
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80014
        • Allianz Research Institute - Aurora- Site Number : 8400026
      • Wheat Ridge, Colorado, Estados Unidos, 80033
        • Western States Clinical Research- Site Number : 8400014
    • Florida
      • Boynton Beach, Florida, Estados Unidos, 33435
        • Helix Biomedics- Site Number : 8400114
      • Cutler Bay, Florida, Estados Unidos, 33157
        • Beautiful Minds Clinical Research Center- Site Number : 8400049
      • Hialeah, Florida, Estados Unidos, 33010
        • Qway Research - Hialeah- Site Number : 8400015
      • Miami, Florida, Estados Unidos, 33184
        • High Quality Research- Site Number : 8400039
      • Miami, Florida, Estados Unidos, 33186
        • Innovations Biotech- Site Number : 8400040
      • Miami, Florida, Estados Unidos, 33186
        • New Access Medical Center- Site Number : 8400043
      • Miami, Florida, Estados Unidos, 33135
        • Clintex Research Group - Miami - Southwest 27th Avenue- Site Number : 8400048
      • Miami Lakes, Florida, Estados Unidos, 33014
        • Deluxe Health Center- Site Number : 8400045
      • Pembroke Pines, Florida, Estados Unidos, 33025
        • Tellabio International Research Services- Site Number : 8400083
      • Pembroke Pines, Florida, Estados Unidos, 33029
        • Alfa Medical Research LLC- Site Number : 8400146
      • Pensacola, Florida, Estados Unidos, 32503
        • Avanza Medical Research Center- Site Number : 8400135
      • Saint Cloud, Florida, Estados Unidos, 34769
        • Ilumina Medical Research- Site Number : 8400095
      • Sarasota, Florida, Estados Unidos, 34239
        • Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019
    • Georgia
      • Cordele, Georgia, Estados Unidos, 31015
        • Private Practice - Dr. David Kavtaradze- Site Number : 8400081
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Brigham & Women's Hospital- Site Number : 8400034
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan Health System - Ann Arbor- Site Number : 8400004
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63141
        • Midwest Clinical Research Center - St. Louis- Site Number : 8400006
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28287
        • Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029
    • Ohio
      • Toledo, Ohio, Estados Unidos, 43617
        • Asthma & Allergy Center - Toledo- Site Number : 8400017
    • Oklahoma
      • Edmond, Oklahoma, Estados Unidos, 73034
        • OK Clinical Research- Site Number : 8400021
    • Pennsylvania
      • DuBois, Pennsylvania, Estados Unidos, 15801
        • Clinical Research Associates of Central Pennsylvania- Site Number : 8400116
      • Pittsburgh, Pennsylvania, Estados Unidos, 15241
        • Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007
    • Texas
      • Austin, Texas, Estados Unidos, 78759
        • Orion Clinical Research- Site Number : 8400001
      • Boerne, Texas, Estados Unidos, 78006
        • South Texas Medical Research Institute - TTS Research- Site Number : 8400010
      • Dallas, Texas, Estados Unidos, 75246
        • Baylor University Medical Center- Site Number : 8400002
      • El Paso, Texas, Estados Unidos, 79903
        • Western Sky Medical Research- Site Number : 8400023
      • McKinney, Texas, Estados Unidos, 75069
        • Metroplex Pulmonary and Sleep Center- Site Number : 8400022
      • Mosonmagyaróvár, Hungria, 9200
        • Investigational Site Number : 3480004
      • Ashkelon, Israel, 7830604
        • Investigational Site Number : 3760006
      • Haifa, Israel, 3104802
        • Investigational Site Number : 3760001
      • Haifa, Israel, 3436212
        • Investigational Site Number : 3760008
      • Jerusalem, Israel, 9103102
        • Investigational Site Number : 3760003
      • Jerusalem, Israel, 9112001
        • Investigational Site Number : 3760002
      • Petah Tikva, Israel, 4941492
        • Investigational Site Number : 3760010
      • Rehovot, Israel, 7610001
        • Investigational Site Number : 3760004
      • Tel Aviv, Israel, 6423906
        • Investigational Site Number : 3760007
    • Roma
      • Rome, Roma, Itália, 00168
        • Investigational Site Number : 3800010
      • Fukushima, Japão, 960-1295
        • Investigational Site Number : 3920008
      • Kyoto, Japão, 610-0113
        • Investigational Site Number : 3920006
      • Kyoto, Japão, 612-8555
        • Investigational Site Number : 3920009
      • Miyazaki, Japão, 889-1692
        • Investigational Site Number : 3920012
    • Kagawa-ken
      • Sakaidechō, Kagawa-ken, Japão, 762-8550
        • Investigational Site Number : 3920002
    • Tokyo
      • Chūō, Tokyo, Japão, 104-0031
        • Investigational Site Number : 3920011
    • Yamaguchi
      • Ube, Yamaguchi, Japão, 755-8505
        • Investigational Site Number : 3920005
      • Chihuahua City, México, 31000
        • Investigational Site Number : 4840002
      • Durango, México, 34000
        • Investigational Site Number : 4840003
      • Veracruz, México, 91900
        • Investigational Site Number : 4840008
    • Nuevo León
      • Monterrey, Nuevo León, México, 66465
        • Investigational Site Number : 4840004
    • Querétaro
      • San Juan del Río, Querétaro, México, 76800
        • Investigational Site Number : 4840005
    • Yucatán
      • Mérida, Yucatán, México, 97070
        • Investigational Site Number : 4840007
      • Chęciny, Polônia, 26-060
        • Investigational Site Number : 6160004
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polônia, 60-693
        • Investigational Site Number : 6160001
      • Bradford, Reino Unido, BD9 6DA
        • Investigational Site Number : 8260008
      • Chertsey, Reino Unido
        • Investigational Site Number : 8260005
      • London, Reino Unido, W1G 8HU
        • Investigational Site Number : 8260011
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Reino Unido, CB2 2QQ
        • Investigational Site Number : 8260001
    • Glasgow City
      • Glasgow, Glasgow City, Reino Unido, G12 0YN
        • Investigational Site Number : 8260004
      • Taipei, Taiwan, 110
        • Investigational Site Number : 1580003
      • Bursa, Turquia (Türkiye), 16059
        • Investigational Site Number : 7920006
      • Istanbul, Turquia (Türkiye), 34098
        • Investigational Site Number : 7920002
      • Istanbul, Turquia (Türkiye), 34854
        • Investigational Site Number : 7920003
      • Kayseri, Turquia (Türkiye), 38039
        • Investigational Site Number : 7920007
      • Kirikkale, Turquia (Türkiye), 71100
        • Investigational Site Number : 7920008
      • Mersin, Turquia (Türkiye), 33070
        • Investigational Site Number : 7920001
      • İzmit, Turquia (Türkiye), 41001
        • Investigational Site Number : 7920005
      • Benoni, África do Sul, 1500
        • Investigational Site Number : 7100004
      • Benoni, África do Sul, 1500
        • Investigational Site Number : 7100005
      • Cape Town, África do Sul, 7530
        • Investigational Site Number : 7100003
      • Cape Town, África do Sul, 7700
        • Investigational Site Number : 7100002
      • Durban, África do Sul, 4001
        • Investigational Site Number : 7100001
      • Pretoria, África do Sul, 0157
        • Investigational Site Number : 7100006
      • Calicut, Índia, 673008
        • Investigational Site Number : 3560007
      • Hyderabad, Índia, 500084
        • Investigational Site Number : 3560009
      • Kanpur, Índia, 208001
        • Investigational Site Number : 3560008
      • Nagpur, Índia, 441203
        • Investigational Site Number : 3560001
      • Pune, Índia, 411057
        • Investigational Site Number : 3560004

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Participants who completed the treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol

  • Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:

    • For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines), with or without oral prednisone
    • For Study ACT18301: LABA with or without LTRA
  • Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures

  • Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:

For female participants:

  • incapable of becoming pregnant, or
  • not pregnant or breast feeding
  • no eggs donation or cryopreserving eggs

For male participants:

-- No sperm donation or cryopreserving sperm

- Capable of giving signed informed consent

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participants potentially at risk of noncompliance to study procedures
  • Participant who was diagnosed with a new pulmonary disease which may impair lung function
  • Current smoker or active vaping of any products and/or marijuana smoking
  • Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Participants who are receiving prohibited concomitant medications
  • Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Lunsekimig

Participants will receive subcutaneous injection of lunsekimig according to established dosing interval

  • Pharmaceutical form: Solution for injection in vial or pre-filled syringe (PFS)
  • Route of administration: Subcutaneous injection
Outros nomes:
  • SAR443765

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Prazo: From study baseline to week 148

Exposure-adjusted incidence rate is defined as the number of patients with at least one specific treatment emergent adverse event in question per 100 patients taking the treatment for 1 year.

From study baseline to week 148

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Annualized rate of asthma exacerbation events
Prazo: From study baseline to weeks 48, 96 and 144
From study baseline to weeks 48, 96 and 144
Change from parent study baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Prazo: From parent study baseline to weeks 48, 96 and 144
From parent study baseline to weeks 48, 96 and 144
Serum lunsekimig concentrations
Prazo: From study baseline to week 144
From study baseline to week 144
Incidence and titer of anti-drug antibodies (ADA) against lunsekimig
Prazo: From study baseline to week 144
From study baseline to week 144
Change from parent study baseline in Asthma Control Questionnaire5 (ACQ-5) score
Prazo: From parent study baseline to weeks 48, 96 and 144

The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control.

From parent study baseline to weeks 48, 96 and 144
Proportion of participants with ≥0.5-point reduction in each ACQ-5 score as compared to parent study baseline score
Prazo: From parent study baseline to weeks 48, 96 and 144

Defined as ACQ-5 responder analysis

From parent study baseline to weeks 48, 96 and 144
Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores
Prazo: From parent study baseline to weeks 48, 96 and 144

The AQLQ(S) + 12 was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7. Higher scores indicate better quality of life.

From parent study baseline to weeks 48, 96 and 144

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de setembro de 2024

Conclusão Primária (Estimado)

20 de janeiro de 2031

Conclusão do estudo (Estimado)

20 de janeiro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

20 de setembro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de setembro de 2024

Primeira postagem (Real)

24 de setembro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

21 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

18 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • LTS17231
  • 2025-522896-27 (Identificador de registro: CTIS)
  • U1111-1303-3645 (Identificador de registro: ICTRP)
  • 2025 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever